Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook

Type B end-of-Phase 2 meeting with U.S. Food and Drug Administration provided additional clarity for TSHA-120 for the treatment of giant axonal neuropathy ultra-rare disease program - FDA... | January 31, 2023

Related Keywords

Canada ,Dallas ,Texas ,United States ,United Kingdom ,Kimberly Lee ,Seanp Nolan ,Carolyn Hawley ,Company Contact ,Drug Administration ,Nasdaq ,Exchange Commission ,Taysha Gene Therapies Inc ,Clinical Program Updates ,Globenewswire Inc ,Corporate Affairs ,Ut Southwestern Gene Therapy Program ,Biologics License Application ,Clinical Trial Application ,Investigational New Drug ,Gene Therapies ,Chief Executive Officer ,Gene Therapy Program ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Taysha Gene Therapies ,Nc Stock Exchange ,News ,Information ,Press Release ,Type , ,Meeting ,Ith ,Wood ,End ,Drug ,Administration ,Rovided ,Dditional ,Clarity ,Or ,The ,Treatment ,F ,Giant ,Axonal ,Neuropathy ,Isease Tsha Us8776191061 ,